Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Andrew Sharobeem (NPI 1629389382)

Field	Value
Entity Type	Individual
Organization	Andrew Sharobeem
Address	5681 W Beverly Ln Ste 100
City	Glendale
State	AZ
ZIP	85306
Taxonomy	Rheumatology Physician
NPI Enumerated	June 28, 2010

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

The provider’s Medicare billing profile is dominated by biologic and infusion services consistent with a rheumatology practice that administers targeted injectable therapies on-site. Highest-revenue drugs include J3262 (tocilizumab), J0129 (abatacept), and J1602 (golimumab), and the presence of multiple infusion/chemotherapy administration codes (96413, 96401, 96415) indicates an operational model with an infusion suite or frequent in-office parenteral drug administration.

Revenue is concentrated in a small number of high-cost drugs: total Medicare revenue is $2.3M and the top 3 Medicare codes by revenue account for 55.3% of this provider's total Medicare revenue. Those top codes individually are J3262 ($525.5K revenue, 22.8%), J0129 ($482.7K revenue, 20.9%), and J1602 ($268.2K revenue, 11.6%), showing dependence on a handful of biologics for the majority of Medicare receipts.

This provider is effectively single-payer at the claims level: there is no Medicaid billing on file (none), so Medicare ($2.3M) constitutes the only recorded public-payer activity. That concentration suggests limited Medicaid patient volume and means payer contracting or reimbursement changes to Medicare will have outsized impact on revenue relative to practices with mixed Medicare/Medicaid flows.

Competitive standing on key biologics is mixed: for J3262 the provider ranks #46 of 618 nationally (93th percentile) and is described in the dataset as having a typical, unremarkable volume for that code, which nevertheless places them above most peers on this specific drug. J0129 ranks #261 of 1221 (79th percentile) and J1602 ranks #233 of 1041 (78th percentile), both characterized as typical, unremarkable national volumes — together these positions indicate the provider is a meaningful but not dominant national participant for its top-administered biologics.

Several non-drug codes show unusually high relative volume and suggest strong procedural throughput: 99214 ranks #17844 of 479517 (96th percentile; notably above typical national volume) and 96413 ranks #316 of 7514 (96th percentile; notably above typical national volume). These percentile placements indicate above-average office visit and infusion administration activity compared with national peers, reinforcing the inference of a busy in-office infusion and outpatient management practice.

Certain drug-specific volumes are statistical outliers in the dataset and may reflect local treatment patterns: J0897 (denosumab) ranks #592 of 10057 (94th percentile; notably above typical national volume), while other specialty injectables such as J9312 (rituximab) rank at more moderate levels (#102 of 317, 67th percentile; typical, unremarkable volume). This mix points to both broadly aligned rheumatology biologic usage and a few therapies where this provider’s relative utilization is clearly above national norms.

Operational breadth is evident from ancillary and procedural codes: the presence of arthrocentesis (20611), bone density testing (77085), joint ultrasound (76881), and on‑site lab panels and draws (80053, 36415, 86140, 82306) indicates an integrated outpatient practice that combines diagnostics, procedural interventions, imaging, and infusion-based therapeutics. That breadth supports end-to-end care for musculoskeletal and inflammatory conditions commonly managed in rheumatology.

The provider has an established billing history with an NPI enumerated 2010-06-28 (~16 years ago), implying practice continuity and tenure in the market. Given the concentration of Medicare revenue in a few biologics and the absence of Medicaid billing, strategic focus on Medicare payer negotiations and supply-chain management for high-cost infused drugs would likely have outsized impact on financial performance.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

60 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3262	Injection, tocilizumab, 1 mg	105,100	$10	$525.5K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	14,630	$30	$482.7K
J1602	Injection, golimumab, 1 mg, for intravenous use	24,380	$10	$268.2K
J9312	Injection, rituximab, 10 mg	4,200	$60	$256.2K
J0897	Injection, denosumab, 1 mg	14,220	$20	$256K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	30,400	$1	$121.6K
J3111	Injection, romosozumab-aqqg, 1 mg	14,700	$10	$117.6K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	830	$90	$75.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	660	$100	$63.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	1,920	$20	$34.6K

Showing 1–10 of 60

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 60 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Andrew Sharobeem — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

60 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	17	30	14,700	$30	$494.5K
J3262	5	20	74,500	$1	$367.2K
J1602	13	30	24,040	$10	$316.2K
J0717	15	20	36,100	$1	$246.6K
J9312	6	20	3,250	$60	$212.6K
J3111	26	40	19,530	$10	$178.8K
J0897	32	260	2,940	$20	$115.6K
J1745	30	40	2,980	$30	$103.9K
86480	11	20	110	$60	$27.2K
86635	13	20	290	$10	$25.8K

Showing 1–10 of 60

Related Providers

Other providers that share a Tax Identification Number (TIN) with Andrew Sharobeem, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arizona Arthritis & Rheumatology Associates P C	AZ	Rheumatology Physician	$0	$11.2M
Nehad Soloman	AZ	Rheumatology Physician	$5.1M	$0
Alexander Hu	AZ	Internal Medicine Physician	$3.8M	$0
Areena Swarup	AZ	Rheumatology Physician	$3.6M	$0
Saima Chohan	AZ	Rheumatology Physician	$3.5M	$0
Nikila Kumar	AZ	Rheumatology Physician	$3M	$0
Hisham El-kadi	NJ	Rheumatology Physician	$3M	$0
John Tesser	AZ	Rheumatology Physician	$3M	$0
Daniel Kreutz	AZ	Rheumatology Physician	$2.8M	$0
Mona Amin	AZ	Rheumatology Physician	$2.7M	$0

Nearby Providers

Other providers in the same ZIP code as Andrew Sharobeem, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Banner Thunderbird Medical Center	AZ	General Acute Care Hospital	$0	$140.1M
North Valley Emergency Specialists	AZ	Emergency Medicine Physician	$0	$23.2M
Emeritus Properties Ngh, LLC	AZ	Assisted Living Facility	$0	$12.1M
Satinder S. Purewal, M.d. LLC	AZ	Psychiatry Physician	$0	$9.4M
Founders Healthcare, LLC	AZ	Durable Medical Equipment & Medical Supplies	$0	$8.9M
Jewish Family & Children's Service	AZ	Community/Behavioral Health Agency	$0	$7.5M
Children's Medical Group, Ltd	AZ	Pediatrics Physician	$0	$7.5M
Adam Leon	AZ	Nurse Practitioner	$2M	$0
Murali Murty	AZ	Radiation Oncology Physician	$1.3M	$0
Daniel Reed	AZ	Radiation Oncology Physician	$1.3M	$0

Andrew Sharobeem — Billing Profile & Reimbursement Data

Sign up for Andrew Sharobeem — Billing Profile & Reimbursement Data policy alerts

Andrew Sharobeem — Billing Profile & Reimbursement Data

Sign up for Andrew Sharobeem — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References